Mirtazapin +pharma (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizing postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This combined action boosts serotonergic and noradrenergic neurotransmission while providing sedative effects, contributing to its antidepressant activity.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments may be made during treatment, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s team will verify eligibility, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its broader receptor profile, including antihistaminic activity that often causes sedation and weight gain. While SSRIs are generally activating, mirtazapine may be preferred when insomnia or appetite stimulation are therapeutic goals.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mirtazapin +pharma is supplied as oral tablets that should be swallowed whole with water. It is typically taken once daily, preferably in the evening, to take advantage of its sedative properties, unless otherwise directed by a healthcare professional.

Serious adverse events, though rare, include agranulocytosis or severe neutropenia, seizures, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, neurological changes, or skin reactions and seek immediate medical attention if they occur.

Mirtazapin +pharma should be avoided in individuals with known hypersensitivity to mirtazapine, those currently taking monoamine oxidase inhibitors, or patients with severe hepatic impairment. Caution is also advised for patients with a history of seizures or blood dyscrasias.